Gilead Sciences (NASDAQ:GILD – Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, August 3rd. Analysts expect the company to announce earnings of $1.63 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, April 27th. The biopharmaceutical company reported $1.37 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.26). Gilead Sciences had a return on equity of 39.35% and a net margin of 20.65%. The company had revenue of $6.35 billion for the quarter, compared to analyst estimates of $6.33 billion. During the same quarter in the previous year, the firm posted $2.12 earnings per share. The company’s quarterly revenue was down 3.6% on a year-over-year basis. On average, analysts expect Gilead Sciences to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Gilead Sciences Trading Down 0.1 %
NASDAQ:GILD opened at $77.19 on Thursday. The company has a market capitalization of $96.28 billion, a P/E ratio of 17.42, a PEG ratio of 0.90 and a beta of 0.38. The firm has a fifty day simple moving average of $77.52 and a 200-day simple moving average of $80.77. Gilead Sciences has a 12 month low of $59.27 and a 12 month high of $89.74. The company has a current ratio of 1.28, a quick ratio of 1.13 and a debt-to-equity ratio of 1.10.
Insider Buying and Selling
In related news, CFO Andrew D. Dickinson sold 5,000 shares of the stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the sale, the chief financial officer now owns 107,587 shares of the company’s stock, valued at approximately $8,606,960. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Merdad Parsey sold 1,485 shares of the firm’s stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $76.90, for a total transaction of $114,196.50. Following the transaction, the insider now owns 29,402 shares of the company’s stock, valued at $2,261,013.80. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $80.00, for a total transaction of $400,000.00. Following the transaction, the chief financial officer now directly owns 107,587 shares in the company, valued at approximately $8,606,960. The disclosure for this sale can be found here. Insiders own 0.21% of the company’s stock.
Hedge Funds Weigh In On Gilead Sciences
A number of institutional investors have recently modified their holdings of GILD. Sanctuary Wealth Management L.L.C. bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $33,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at $36,000. Pacific Center for Financial Services acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at $47,000. McIlrath & Eck LLC boosted its stake in shares of Gilead Sciences by 30.7% in the 4th quarter. McIlrath & Eck LLC now owns 736 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 173 shares in the last quarter. Finally, Cowa LLC bought a new position in shares of Gilead Sciences in the first quarter valued at about $132,000. Institutional investors own 81.59% of the company’s stock.
Analyst Upgrades and Downgrades
GILD has been the subject of a number of research reports. StockNews.com initiated coverage on shares of Gilead Sciences in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. BMO Capital Markets decreased their target price on shares of Gilead Sciences from $100.00 to $95.00 in a research report on Tuesday, July 18th. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a report on Wednesday, April 12th. Cantor Fitzgerald cut their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, July 19th. Finally, Barclays cut their price objective on shares of Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $90.45.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Gilead Sciences wasn’t on the list.
While Gilead Sciences currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven best retirement stocks and why they should be in your portfolio.
